Alfred Altomari, Director at Recro Pharma, Inc. (REPH), bought 1,500 shares at $6.55 ($10K) on 2016-12-15, disclosed to the SEC on 2016-12-16.
Open-market purchase of $10k REPH by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| AGRX | BUY | 2021-05-19 | $32K | — | Filing → |
| AGRX | BUY | 2021-03-23 | $25K | — | Filing → |
| INSM | SELL | 2020-12-09 | $791K | — | Filing → |